A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
This study has been completed.
Information provided by (Responsible Party):
First received: January 5, 2010
Last updated: November 1, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2012|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||July 8, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180.